Interleukin-1 cluster combined genotype and restenosis after balloon angioplasty

The interleukin-1 system is fundamentally involved in the pathogenesis of restenosis after percutaneous transluminal angioplasty (PTA). In order to further define the clinical impact of genetic variation in this potent proinflammatory pathway we investigated the joint effects of two single nucleotid...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 90; no. 3; p. 491
Main Authors Marculescu, Rodrig, Mlekusch, Wolfgang, Exner, Markus, Sabeti, Schila, Michor, Stefanie, Rumpold, Helmut, Mannhalter, Christine, Minar, Erich, Wagner, Oswald, Schillinger, Martin
Format Journal Article
LanguageEnglish
Published Germany 01.09.2003
Subjects
Aged
Aged, 80 and over
Angioplasty, Balloon, Coronary - adverse effects
Arteriosclerosis - genetics
Coronary Restenosis - genetics
Female
Gene Dosage
Genotype
Humans
Inflammation - genetics
Interleukin 1 Receptor Antagonist Protein
Interleukin-1 - genetics
Linkage Disequilibrium
Male
Multigene Family
Mutation
Polymorphism, Genetic
Sialoglycoproteins - genetics
Online AccessGet more information

Cover

More Information
Summary:The interleukin-1 system is fundamentally involved in the pathogenesis of restenosis after percutaneous transluminal angioplasty (PTA). In order to further define the clinical impact of genetic variation in this potent proinflammatory pathway we investigated the joint effects of two single nucleotide polymorphisms in the interleukin-1 beta gene [IL-1B(-511) and IL-1B(+3954)] and a variable number tandem repeat polymorphism in intron 2 of the interleukin 1 receptor antagonist gene (IL-1RN VNTR) on postintervention inflammation and occurrence of restenosis in 183 consecutive patients who underwent successful femoropopliteal PTA. C-reactive protein (CRP) and serum amyloid A (SAA) were determined pre- and 48 hours postintervention. Patients were followed up to 12 months for the occurrence of postangioplasty restenosis (> or = 50%). When analyzed separately, none of the polymorphisms was associated either with inflammation or restenosis. However, when the IL-1B (-511) and the IL-1RN VNTR genotypes were combined, a highly significant relationship was observed: Non-carriers of the two repeat allele of the IL-1RN VNTR (IL-1RN*2) who were heterozygous and homozygous for the IL-1B (-511)T allele exhibited a gradually increased inflammatory response and a higher restenosis risk. In contrast, carriers of the IL-1RN*2 and the IL-1B (-511)T allele showed a significantly better outcome. This remarkable gene dose-dependent association emphasizes the advantage of considering combinations of genetic markers rather that isolated polymorphisms in the analysis of multifactorial vascular disease.
ISSN:0340-6245